Quipt Home Medical announced the voting results from its annual general and special meeting of shareholders held on March 27, 2024 in Wilder, Kentucky. The total number of shares represented in person or by proxy at the Meeting was 25,432,699, representing 60.4% of the total issued and outstanding shares in the capital of the Company. The four candidates nominated for election to the Company’s Board of Directors and listed in the Company’s management information and proxy circular dated February 14, 2024, were elected by at least a majority of the shareholders present in person or represented by proxy at the Meeting. The Company’s shareholders have approved the re-appointment of BDO USA, P.C. as the auditor of the Company for the fiscal year ended December 31, 2024 and authorized the Board to fix the auditor’s remuneration. The Company’s shareholders have approved the 2024 Equity Incentive Plan of the Company, pursuant to which the Company is able to issue share-based long-term incentives. All directors, officers, employees and service providers of the Company and/or its affiliates are eligible to receive awards under the Incentive Plan, subject to the terms of the Incentive Plan. Awards include common share purchase options, stock appreciation rights, restricted share awards, restricted share bonuses, restricted share units, performance shares, performance units, cash-based awards, and other share-based awards under the Incentive Plan. A copy of the Incentive Plan is attached as Schedule “A” to the Circular. As a result of the adoption of the Incentive Plan, no future awards or grants will be made under the Company’s current equity incentive plan, which became effective on May 3, 2021.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QIPT:
- Quipt Home Medical Announces Voting Results from Its Annual General and Special Meeting of Shareholders
- Quipt Home Medical to Attend Roth Investor Conference
- Quipt Home Medical Announces Participation in the 36th Annual Roth Investor Conference on March 17-19, 2024
- Quipt Home Medical price target lowered to C$10.50 from C$12.75 at Stifel
- Quipt Home Medical downgraded to Market Perform from Outperform at Raymond James